<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="129494">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01416311</url>
  </required_header>
  <id_info>
    <org_study_id>114877</org_study_id>
    <nct_id>NCT01416311</nct_id>
  </id_info>
  <brief_title>Drug Use Investigation for REVOLADE (ITP)</brief_title>
  <official_title>Drug Use Investigation for REVOLADE (Chronic Idiopathic Thrombocytopenic Purpura)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate safety and efficacy in the actual use of REVOLADE collected from all subjects
      receiving the drug until data from a specified number of subjects are accumulated to
      identify factors considered to influence its safety and efficacy.

      &lt;Priority investigation item&gt; Thromboembolism
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Anticipated">December 27, 2018</completion_date>
  <primary_completion_date type="Anticipated">December 27, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The number of subjects with any adverse events treated with REVOLADE</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Appearance of thromboembolism</measure>
    <time_frame>1 year</time_frame>
    <description>If thromboembolism is appeared or not in subjects who received REVOLADE will be investigated throughout the study period</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Purpura, Thrombocytopaenic, Idiopathic</condition>
  <arm_group>
    <arm_group_label>Subjects prescribed REVOLADE</arm_group_label>
    <description>Subjects with chronic idiopathic thrombocytopenic purpura prescribed REVOLADE during study period</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eltrombopag</intervention_name>
    <arm_group_label>Subjects prescribed REVOLADE</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All Japanese subjects with chronic idiopathic thrombocytopenic purpura who recieve
        REVOLADE
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with chronic idiopathic thrombocytopenic purpura

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 28, 2017</lastchanged_date>
  <firstreceived_date>June 9, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Purpura</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
